Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 11/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 14/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3770697 | 0.99 | HDAC2 (0.60) | HDAC2HDAC1HDAC3KCNH2PTPN1 | |
| SCHEMBL3764529 | 0.98 | HDAC2 (0.61) | HDAC2HDAC1HDAC3KCNH2PTPN1 | |
| SCHEMBL3760016 | 0.96 | HDAC2 (0.63) | HDAC2HDAC1HDAC3KCNH2PTPN1 | |
| SCHEMBL7767369 | 0.91 | HDAC3 (0.60) | HDAC2HDAC1HDAC3KCNH2 | |
| SCHEMBL15397948 | 0.82 | HDAC2 (0.76) | HDAC2HDAC1HDAC3PTPN1NCOR2 | |
| SCHEMBL3769890 | 0.81 | HDAC1 (0.73) | HDAC2HDAC1HDAC3KCNH2 | |
| SCHEMBL3764431 | 0.79 | HDAC1 (0.52) | HDAC2HDAC1HDAC3KCNH2NCOR2 | |
| SCHEMBL3766669 | 0.79 | HDAC2 (0.53) | HDAC2HDAC1HDAC3KCNH2NCOR2 | |
| SCHEMBL28848243 | 0.79 | HDAC1 (0.52) | HDAC1 | |
| SCHEMBL1708159 | 0.77 | HDAC1 (0.46) | HDAC2HDAC1HDAC3KCNH2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440517-B1 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2014-03-26 | — | — | EP | disclosed |
| EP-2440517-B1 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2014-03-26 | — | — | EP | disclosed |
| US-8283357-B2 | Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-8283357-B2 | Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-8283357-B2 | Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-20100311794-A1 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311794-A1 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311794-A1 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311794-A1 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | HDAC1, HDAC5, HDAC3 | HDAC2 4/4885HDAC1 1/4885HDAC3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.